Hospital & Healthcare Services · Founded 1998 · www.rainbowhospitals.in · BSE 543524 · NSE RAINBOW · ISIN INE961O01016
No Notes Added Yet
Business
Rainbow Children's Medicare Ltd. is an India-based company operating a chain of multi-specialty hospitals primarily focused on pediatric, obstetrics, and gynecology healthcare services. Its core business model involves establishing and managing specialized hospitals that cater specifically to the healthcare needs of children and women, from birth to adolescence and throughout various stages of womanhood, including fertility services. The company makes money by providing a comprehensive range of medical services, including out-patient consultations, in-patient admissions, surgeries, diagnostics, intensive care, pharmacy services, and other allied healthcare services.
Revenue Mix
The company's primary services, which can be considered its key segments, are:
Pediatric Care: Covering various specialties like pediatric intensive care, neonatal intensive care, pediatric cardiology, neurology, nephrology, oncology, and general pediatrics.
Obstetrics & Gynecology: Services include maternal care, high-risk pregnancy management, fertility services, general gynecology, and gynecological surgeries.
Allied Services: Diagnostic services, pharmacy, and other support services that complement the core medical offerings.
Revenue is generated predominantly from in-patient (IPD) and out-patient (OPD) services across these specialities.
Industry
The Indian hospital and healthcare services industry is large, growing, and increasingly sophisticated, driven by rising disposable incomes, health awareness, and insurance penetration. It is characterized by a mix of unorganized standalone facilities and a growing number of organized hospital chains. Rainbow Children's Medicare Ltd. holds a unique and strong position as one of the largest organized and specialized players in the pediatric and maternal care segment. Its niche focus differentiates it from general multi-specialty hospitals, allowing it to build expertise and a reputation for sensitive and specialized care within this high-demand segment.
MOAT
Specialization & Brand Reputation: A focused approach on pediatric and women's healthcare has allowed Rainbow to build deep expertise and a trusted brand, particularly in sensitive areas like neonatal and pediatric intensive care, where parents seek the best possible outcomes. This specialization creates a strong preference among target customers.
Clinical Excellence & Talent: Attracting and retaining highly specialized doctors and medical staff in pediatrics and obstetrics is critical. Rainbow's established network and focus enable it to build and maintain teams of experts, which is a significant barrier for new entrants.
Network Effect (within niche): As the company expands its network of specialized hospitals, it can leverage cross-referrals and centralize certain high-end services, enhancing its operational efficiency and patient access.
Growth Drivers
Demographic Tailwinds: India's large young population and high birth rate provide a substantial and continuous demand pool for pediatric and maternal healthcare.
Under-penetration of Specialized Care: There is a significant gap in organized, high-quality specialized pediatric and women's healthcare across many Indian cities, offering ample room for expansion.
Network Expansion: Opening new hospitals in existing and new Tier-1 and Tier-2 cities is a key growth strategy to tap into unserved markets.
Rising Healthcare Expenditure: Increasing affluence and greater awareness lead to higher out-of-pocket spending and health insurance adoption for quality healthcare.
Focus on Medical Tourism: The specialized nature of Rainbow's services could attract patients from other countries seeking advanced pediatric and maternal care.
Risks
Talent Acquisition & Retention: Shortage of highly specialized medical professionals (pediatricians, neonatologists, obstetricians) and intense competition for talent can drive up costs.
Regulatory Changes: Government interventions on healthcare pricing, land allotment, or quality standards could impact profitability and operational flexibility.
Competition: Increasing competition from other organized hospital chains looking to enter or expand within the specialized mother and child care segment.
High Capital Expenditure: Expansion through new hospital development requires significant capital investment, which can strain finances and impact short-term profitability.
Quality & Reputation Risk: Any lapse in medical quality or patient care across its growing network could severely damage its specialized brand reputation.
Management & Ownership
Rainbow Children's Medicare Ltd. is a promoter-led company, founded by Dr. Ramesh Kancharla, who has extensive experience in the healthcare sector, particularly in pediatric care. The management team generally comprises professionals with medical and administrative backgrounds relevant to hospital operations. The ownership structure includes a significant promoter holding, with a portion of shares publicly listed and held by institutional investors and the public. The promoter-led nature typically implies a strong focus on the core business vision and long-term strategy.
Outlook
Rainbow Children's Medicare benefits from robust demand in the under-penetrated specialized pediatric and maternal healthcare segment in India, driven by favorable demographics and increasing affordability. Its strong brand, clinical expertise, and strategic expansion plans position it well for sustained growth, leveraging its niche advantage to attract patient volumes and potentially improve operating leverage over time. However, the company faces considerable challenges including intense competition for specialized medical talent, the high capital intensity of hospital expansion, and potential regulatory risks. Maintaining consistent quality across a rapidly expanding network is crucial for preserving its trusted brand. While the long-term structural tailwinds for specialized healthcare are strong, significant execution risks and capital commitments mean that growth may come with near-term pressure on profitability and require careful management of resources and quality standards.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 336 | 341 | 330 | 417 | 398 | 370 | 353 | 445 | 445 | 460 |
| Other Income | 9 | 13 | 12 | 11 | 13 | 15 | 20 | 8 | 11 | 5 |
| Total Income | 345 | 354 | 342 | 429 | 411 | 385 | 373 | 453 | 456 | 465 |
| Total Expenditure | 218 | 236 | 236 | 270 | 264 | 255 | 249 | 296 | 298 | 315 |
| Operating Profit | 127 | 118 | 106 | 158 | 148 | 129 | 124 | 157 | 157 | 150 |
| Interest | 14 | 17 | 18 | 18 | 18 | 18 | 18 | 19 | 20 | 20 |
| Depreciation | 28 | 32 | 34 | 35 | 35 | 34 | 34 | 36 | 40 | 41 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |
| Profit Before Tax | 85 | 69 | 53 | 105 | 94 | 77 | 71 | 102 | 98 | 87 |
| Provision for Tax | 22 | 18 | 14 | 26 | 25 | 20 | 18 | 27 | 24 | 9 |
| Profit After Tax | 63 | 51 | 40 | 79 | 69 | 57 | 54 | 76 | 74 | 78 |
| Adjustments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -1 |
| Profit After Adjustments | 62 | 51 | 40 | 79 | 69 | 56 | 53 | 75 | 73 | 77 |
| Adjusted Earnings Per Share | 6.1 | 5 | 3.9 | 7.8 | 6.8 | 5.5 | 5.3 | 7.4 | 7.1 | 7.6 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 321 | 402 | 543 | 719 | 650 | 974 | 1174 | 1297 | 1516 | 1703 |
| Other Income | 11 | 10 | 8 | 10 | 10 | 19 | 31 | 37 | 51 | 44 |
| Total Income | 332 | 411 | 551 | 730 | 660 | 993 | 1204 | 1334 | 1567 | 1747 |
| Total Expenditure | 266 | 332 | 431 | 519 | 485 | 666 | 774 | 865 | 1022 | 1158 |
| Operating Profit | 66 | 79 | 120 | 211 | 175 | 327 | 430 | 469 | 545 | 588 |
| Interest | 3 | 4 | 6 | 48 | 46 | 56 | 58 | 63 | 77 | 77 |
| Depreciation | 22 | 28 | 37 | 69 | 73 | 83 | 90 | 112 | 138 | 151 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |
| Profit Before Tax | 41 | 47 | 78 | 93 | 56 | 187 | 282 | 295 | 330 | 358 |
| Provision for Tax | 10 | 11 | 20 | 38 | 16 | 49 | 69 | 77 | 86 | 78 |
| Profit After Tax | 31 | 36 | 58 | 55 | 40 | 139 | 212 | 218 | 244 | 282 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | -2 | -1 | -1 | -2 |
| Profit After Adjustments | 31 | 36 | 58 | 56 | 40 | 138 | 211 | 217 | 243 | 278 |
| Adjusted Earnings Per Share | 3.4 | 4 | 6.4 | 6.2 | 4.4 | 14.7 | 20.8 | 21.4 | 24 | 27.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 17% | 16% | 16% | 0% |
| Operating Profit CAGR | 16% | 19% | 21% | 0% |
| PAT CAGR | 12% | 21% | 35% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -5% | 12% | NA% | NA% |
| ROE Average | 18% | 21% | 20% | 17% |
| ROCE Average | 30% | 34% | 33% | 27% |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 329 | 362 | 416 | 405 | 446 | 603 | 1060 | 1259 | 1468 |
| Minority's Interest | 0 | 0 | 0 | 4 | 2 | 3 | 5 | 6 | 7 |
| Borrowings | 10 | 10 | 50 | 46 | 41 | 27 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4 | 5 | 7 | 472 | 468 | 526 | 541 | 730 | 722 |
| Total Current Liabilities | 56 | 70 | 86 | 171 | 122 | 125 | 139 | 149 | 151 |
| Total Liabilities | 399 | 448 | 559 | 1098 | 1078 | 1284 | 1745 | 2144 | 2347 |
| Fixed Assets | 174 | 296 | 344 | 702 | 772 | 858 | 931 | 1253 | 1398 |
| Other Non-Current Assets | 100 | 79 | 78 | 153 | 109 | 136 | 336 | 270 | 127 |
| Total Current Assets | 126 | 73 | 136 | 244 | 197 | 290 | 478 | 622 | 822 |
| Total Assets | 399 | 448 | 559 | 1098 | 1078 | 1284 | 1745 | 2144 | 2347 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 5 | 3 | 5 | 7 | 6 | 10 | 17 | 10 |
| Cash Flow from Operating Activities | 36 | 48 | 90 | 170 | 143 | 224 | 329 | 321 | 396 |
| Cash Flow from Investing Activities | -33 | -42 | -117 | -117 | -83 | -175 | -465 | -226 | -268 |
| Cash Flow from Financing Activities | -1 | -7 | 28 | -52 | -61 | -44 | 143 | -102 | -118 |
| Net Cash Inflow / Outflow | 1 | -2 | 2 | 2 | -1 | 4 | 7 | -7 | 10 |
| Closing Cash & Cash Equivalent | 5 | 3 | 5 | 7 | 6 | 10 | 17 | 10 | 20 |
| # | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.43 | 3.96 | 6.4 | 6.18 | 4.44 | 14.7 | 20.77 | 21.38 | 23.97 |
| CEPS(Rs) | 5.9 | 7.14 | 10.52 | 13.84 | 12.53 | 23.6 | 29.82 | 32.55 | 37.68 |
| DPS(Rs) | 2.5 | 1 | 1 | 2 | 0 | 2 | 3 | 3 | 3 |
| Book NAV/Share(Rs) | 35.24 | 38.93 | 44.88 | 43.77 | 48.32 | 62.93 | 104.42 | 123.08 | 144.41 |
| Core EBITDA Margin(%) | 17.1 | 17.3 | 20.61 | 27.9 | 25.4 | 31.61 | 34.05 | 33.34 | 32.6 |
| EBIT Margin(%) | 13.74 | 12.7 | 15.35 | 19.69 | 15.7 | 25.01 | 28.99 | 27.55 | 26.84 |
| Pre Tax Margin(%) | 12.84 | 11.64 | 14.3 | 12.98 | 8.57 | 19.24 | 24.01 | 22.73 | 21.77 |
| PAT Margin (%) | 9.76 | 9.03 | 10.67 | 7.69 | 6.09 | 14.24 | 18.1 | 16.83 | 16.11 |
| Cash Profit Margin (%) | 16.57 | 16.02 | 17.47 | 17.34 | 17.37 | 22.79 | 25.79 | 25.47 | 25.24 |
| ROA(%) | 7.86 | 8.57 | 11.51 | 6.68 | 3.64 | 11.74 | 14.02 | 11.23 | 10.87 |
| ROE(%) | 9.87 | 10.85 | 15.34 | 13.85 | 9.54 | 27 | 25.72 | 18.91 | 17.99 |
| ROCE(%) | 12.83 | 14.2 | 19.81 | 30.56 | 21.42 | 42.92 | 39.96 | 30.82 | 29.83 |
| Receivable days | 15.54 | 13.2 | 14.78 | 18.4 | 24.69 | 15.81 | 14.24 | 17.12 | 17.79 |
| Inventory Days | 7.65 | 5.78 | 4.36 | 5.83 | 7.32 | 4.67 | 5.22 | 6.01 | 6.21 |
| Payable days | 142.04 | 134.98 | 134.76 | 161.38 | 197.76 | 110.68 | 165.2 | 177.11 | 161.48 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 35.16 | 60.71 | 58.39 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 6.99 | 10.55 | 9.69 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0.41 | 0.23 | 0.21 |
| EV/Net Sales(x) | -0.16 | 0.08 | 0.06 | 0.02 | 0.01 | -0.04 | 6.28 | 10.15 | 9.36 |
| EV/Core EBITDA(x) | -0.8 | 0.41 | 0.25 | 0.06 | 0.03 | -0.12 | 17.11 | 28.04 | 26.03 |
| Net Sales Growth(%) | 0 | 25.07 | 35.08 | 32.54 | -9.64 | 49.8 | 20.52 | 10.51 | 16.88 |
| EBIT Growth(%) | 0 | 15.65 | 63.19 | 69.99 | -27.93 | 138.58 | 39.69 | 5.05 | 13.84 |
| PAT Growth(%) | 0 | 15.74 | 59.67 | -4.47 | -28.5 | 250.47 | 53.15 | 2.78 | 11.88 |
| EPS Growth(%) | 0 | 15.65 | 61.61 | -3.41 | -28.19 | 231.04 | 41.3 | 2.93 | 12.12 |
| Debt/Equity(x) | 0.05 | 0.04 | 0.12 | 0.14 | 0.1 | 0.07 | 0 | 0 | 0 |
| Current Ratio(x) | 2.26 | 1.03 | 1.58 | 1.42 | 1.61 | 2.32 | 3.44 | 4.16 | 5.46 |
| Quick Ratio(x) | 2.14 | 0.95 | 1.5 | 1.33 | 1.53 | 2.2 | 3.31 | 4 | 5.28 |
| Interest Cover(x) | 15.25 | 11.96 | 14.64 | 2.93 | 2.2 | 4.34 | 5.83 | 5.71 | 5.3 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 49.83 | 49.83 | 49.88 | 49.85 | 49.85 | 49.85 | 49.85 | 49.85 | 49.84 | 49.84 |
| FII | 22.32 | 24.04 | 24.78 | 25.11 | 25.12 | 23.69 | 23.59 | 21.85 | 19.23 | 17.24 |
| DII | 15.62 | 14.76 | 13.8 | 13.83 | 13.87 | 15.31 | 15.44 | 17.46 | 19.49 | 21.13 |
| Public | 12.23 | 11.37 | 11.54 | 11.2 | 11.16 | 11.14 | 11.11 | 10.84 | 11.44 | 11.79 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| FII | 2.27 | 2.44 | 2.52 | 2.55 | 2.55 | 2.41 | 2.4 | 2.22 | 1.95 | 1.75 |
| DII | 1.59 | 1.5 | 1.4 | 1.4 | 1.41 | 1.56 | 1.57 | 1.77 | 1.98 | 2.15 |
| Public | 1.24 | 1.15 | 1.17 | 1.14 | 1.13 | 1.13 | 1.13 | 1.1 | 1.16 | 1.2 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.15 | 10.15 | 10.15 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +17% | +16% | +16% | — |
| Operating Profit CAGR | +16% | +19% | +21% | — |
| PAT CAGR | +12% | +21% | +35% | — |
| Share Price CAGR | -5% | +12% | — | — |
| ROE Average | +18% | +21% | +20% | +17% |
| ROCE Average | +30% | +34% | +33% | +27% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 49.83 | 49.83 | 49.88 | 49.85 | 49.85 | 49.85 | 49.85 | 49.85 | 49.84 | 49.84 |
| FII | 22.32 | 24.04 | 24.78 | 25.11 | 25.12 | 23.69 | 23.59 | 21.85 | 19.23 | 17.24 |
| DII | 15.62 | 14.76 | 13.8 | 13.83 | 13.87 | 15.31 | 15.44 | 17.46 | 19.49 | 21.13 |
| Public | 50.17 | 50.17 | 50.12 | 50.15 | 50.15 | 50.15 | 50.15 | 50.15 | 50.16 | 50.16 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| FII | 2.27 | 2.44 | 2.52 | 2.55 | 2.55 | 2.41 | 2.4 | 2.22 | 1.95 | 1.75 |
| DII | 1.59 | 1.5 | 1.4 | 1.4 | 1.41 | 1.56 | 1.57 | 1.77 | 1.98 | 2.15 |
| Public | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.15 | 10.15 | 10.15 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.